- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01610427
Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
Optimizing the Quality of Samples Used for the Evaluation of Cell-mediated Immune (CMI) Responses in Antiretroviral Therapy (ART)-naïve Human Deficiency Virus Type 1 (HIV-1)-Infected Subjects
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Gent, Belgien, 9000
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
All subjects must satisfy all the following criteria at study entry:
- Subjects who the Investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject prior to any study procedure.
- A male or female between and including 18 and 55 years of age at the time of enrollment.
- Confirmed HIV-1 infection.
- ART-naïve and not eligible for ART treatment as per established guidelines. Subjects must never have received ART after HIV diagnosis, including lamivudine used for chronic hepatitis B infection. The exception to this is short-term ART for prevention of mother-to-child transmission (PMTCT) which must have been completed at least 360 days prior to enrollment.
- Viral load level between and including 2,000 and 100,000 copies/mL at screening.
- CD4+ T cell count >500 cells/mm3 at screening.
If the subject is female, she must be of non-childbearing potential, i.e., have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal. Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test at screening, and
- has agreed to continue adequate contraception during the entire study period.
Exclusion Criteria:
The following criteria should be checked at the time of study entry. If any exclusion criterion applies, the subject must not be included in the study:
- Infection with HIV-2. This includes subjects with dual infection with HIV-1/HIV-2.
- Planned use of any hematotoxic product during the study period.
- Planned use of any investigational or non-registered product during the study period.
- Acute or chronic, clinically relevant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination, serology and/or medical history at screening.
- Grade 3 or grade 4 laboratory abnormalities, as defined by Division of AIDS (DAIDS) grading table, at screening.
- Any condition which, in the opinion of the Investigator, could compromise the subject's adherence to the study protocol.
- Planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the Sample Collection Visit (Visit 2). Vaccine can be administered as after sampling in Visit 2.
- Pregnant or lactating female.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: HIV-1 Group
Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected.
No investigational vaccine was administered.
|
Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Lymphocytes Viability Prediction (LOGIT Transformed) in CMI Samples Post-overnight Incubation Time Before Intracellular Cytokine Staining (ICS): "Intercept" Parameter Estimate of the Prediction Model - Condition "None" Resting Time Not Included
Zeitfenster: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10^P/(1 + 10^P)*100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting the intercept i.e. expected mean value of Prediction when "TP" and "RT" = 0.
The optimum of this Design of Experiment is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Time to Process and Resting Time Parameter Estimates of the Prediction Model - Condition "None" Resting Time Not Included
Zeitfenster: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting "TP" and "RT" estimates expressed as log(hours).
The optimum of this Design of Experiment (DOE) is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: TP*RT, TP*TP and RT*RT Parameter Estimates of the Prediction Model - Condition "None" Resting Time Not Included
Zeitfenster: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting TP*RT, TP*TP and RT*RT estimates expressed as log(hours^2).
The optimum of this DOE is presented in outcome 4.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (LOGIT Transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Optimum Mean Cell Viability Estimate by the Prediction Model - Condition "None" Resting Time Not Included
Zeitfenster: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=2h, 6h or 18h ["none" resting time not included]) conditions to select the best combination of these two parameters to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.The optimum of the viability was predicted as P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + a*a*TP*TP + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the 3 first primary outcomes.
And a and b are log-transformed parameters corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
The optimum predicted mean cell viability of this Design of Experiment is presented in this outcome and expressed as percentage.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: "Intercept" Parameter Estimate of the Prediction Model - Condition "None" Resting Time Included
Zeitfenster: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting the intercept i.e. expected mean value of Prediction when "TP" and "RT" = 0.
The optimum of this Design of Experiment is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Time to Process and Resting Time Parameter Estimates of the Prediction Model - Condition "None" Resting Time Included
Zeitfenster: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting "TP" and "RT" estimates expressed as log(hours).
The optimum of this Design of Experiment (DOE) is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: TP*RT and RT*RT Parameter Estimates of the Prediction Model - Condition "None" Resting Time Included
Zeitfenster: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
This outcome is presenting TP*RT and RT*RT estimates expressed as log(hours^2).
The optimum of this DOE is presented in outcome 8.
|
At Day 15 (sample collection visit)
|
Lymphocytes Viability Prediction (Non-transformed Estimate) in CMI Samples Post-overnight Incubation Time Before ICS: Optimum Mean Cell Viability Estimates by the Prediction Model -Condition "None" Resting Time Included.
Zeitfenster: At Day 15 (sample collection visit)
|
The objective was to model lymphocyte viability according to "time-to-process" (TP=2h, 7h or 24h) and "resting time" (RT=0h) conditions in order to select the best combination of these two parameters with the aim to maximize the post-ICS viability in CMI samples collected from ART-naïve HIV-1-infected subjects.
Viability (%) = 10 ^ P / (1 + 10 ^ P) * 100 with P for Prediction.
The optimum of the viability was predicted as follows.
P (LOGIT)= intercept + a*TP + b*RT + a*b*TP*RT + + b*b*RT*RT.
Where "intercept", "TP", "RT", "TP*RT", "TP *TP", "RT*RT" are the parameters evaluated and presented in the primary outcomes 5, 6 and 7.
And "a" and "b" are parameters (hour) corresponding respectively to the "TP" and the "RT" where the prediction has to be done.
The optimum predicted mean cell viability of this Design of Experiment is presented in this outcome and expressed as percentage.
|
At Day 15 (sample collection visit)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Viable Lymphocytes in the CMI Samples, Post-overnight Incubation (Classic) Before ICS and Post-6 Hour Incubation Before ICS
Zeitfenster: A Day 15 (sample collection visit)
|
The percentage of viable lymphocytes was determined by Forward Scatter/Side Scatter (FSC/SSC) and LIVE/DEAD gating during flow cytometry analysis for each incubation of time-to-time process (TP) = 2h, 7h and 24 h and resting time (RT) = 18h for the comparison of resting time = 18h and classic incubation time versus resting time = 18h and post-6h incubation time.
|
A Day 15 (sample collection visit)
|
Magnitude of HIV-1 RT Specific Cluster of Differentiation 40 Ligand (CD40L+) CD4+ T Cell Responses in the CMI Samples Post-overnight ICS/Post 6 Hour ICS, Expressing at Least One Cytokine
Zeitfenster: At Day 15 (sample collection visit)
|
Data were collected but could not be reported as data were below level of detection.
|
At Day 15 (sample collection visit)
|
Magnitude of HIV-RT Specific (Background Reduced) CD8+ T Cell Responses in the CMI Samples Post-overnight ICS/Post 6 Hour ICS, Expressing at Least One Cytokine
Zeitfenster: At Day 15 (sample collection visit)
|
HIV-RT specific responses of CD8+ T cells expressing at least one cytokine, among: Interleukin-2 (IL-2), Interferon-gamma (IFN-g) and Tumor necrosis factor alpha (TNF-a),after stimulation with HIV-1 peptide pools for time-to-process (TP) (2, 7, 24 hours) and resting time (RT) (0,2,6,18 hours) post-overnight ICS and for time-to-process (7 hours) and resting time (18 hours) post 6 hours ICS.
|
At Day 15 (sample collection visit)
|
Number of Subjects With Serious Adverse Events (SAEs)
Zeitfenster: During the whole study period (From Day 0 to Day 15)
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitali-zation or prolongation of hospitalization or result in disability/incapacity.
|
During the whole study period (From Day 0 to Day 15)
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 116329
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur AIDS
-
Atara BiotherapeuticsRekrutierungLymphoproliferative Erkrankungen | Leiomyosarkom | Komplikationen bei der Stammzelltransplantation | Komplikationen bei der Transplantation solider Organe | Epstein-Barr-Virus (EBV)-assoziierte Krankheiten | EBV+ Lymphoproliferative Erkrankung nach Transplantation (EBV+ PTLD) | Allogene hämatopoetische... und andere BedingungenVereinigte Staaten, Österreich, Belgien, Frankreich, Italien, Spanien, Vereinigtes Königreich
-
Atara BiotherapeuticsNicht länger verfügbarLymphoproliferative Erkrankungen | Komplikationen bei der Stammzelltransplantation | Epstein-Barr-Virus (EBV)-Infektionen | EBV+ assoziiertes Lymphom | EBV+-assoziierte lymphoproliferative Erkrankung nach Transplantation (EBV+ PTLD) | Epstein-Barr-Virämie | Lymphom, AIDS-bedingt | Epstein-Barr-Virus-assoziierte... und andere Bedingungen
Klinische Studien zur Blood sample collection
-
Hillel Yaffe Medical CenterUnbekannt
-
Acorai ABRekrutierung
-
Cliniques universitaires Saint-Luc- Université...Université de LiègeRekrutierungMukoviszidose | BiomarkerBelgien
-
Heinrich-Heine University, DuesseldorfChugai Pharma USA; Terumo BCTAbgeschlossenGesunde allogene Spender | Mobilisierter Granulozyten-Kolonie-stimulierender Faktor (G-CSF).Deutschland
-
Memorial Sloan Kettering Cancer CenterAbgeschlossenProstatakrebsVereinigte Staaten
-
Cerus CorporationRekrutierungAnämieVereinigte Staaten, Puerto Rico
-
Haydarpasa Numune Training and Research HospitalAbgeschlossenBlutgerinnungsstörungTruthahn
-
University Hospital, RouenNoch keine RekrutierungHepatitis B | Hepatitis C | AIDSFrankreich
-
George Fox UniversityUnbekanntMuskelschwäche | Kann eine Therapie zur Einschränkung des Blutflusses den Kraftzuwachs in der Rotatorenmanschette steigern?Vereinigte Staaten
-
HemanextAbgeschlossenVollblutspende und LeukoreduktionVereinigte Staaten